Robbie Marcus (J.P. Morgan) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Robbie Marcus's stock ratings?

About 56% of Robbie's ratings were profitable over a one-year hold, with an average return of +6.9% per rating, measured by 13Foresight from historical prices.

Q: How is Robbie ranked?

Robbie Marcus is ranked #1058 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Robbie Marcus

JPM

Robbie Marcus

J.P. Morgan

Wall Street Analyst

★★★☆☆

#1058

on 13Foresight · ranked by our own returns

56%

Success Rate

+6.9%

Average Return

20 of 36 calls profitable · +8.9% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 56% of Robbie Marcus's ratings turned a profit when each position was held for 1 year — averaging +6.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

35 Buy 39 Hold 8 Sell

Robbie's Stock Coverage 37 ratings · 2026-06-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
MDT Medtronic	Jun 05, 2026	HOLD	Buy +23.5% avg upside 38 analysts	$86.00 8.32% Upside	-2.9%
COO Cooper Co	Jun 05, 2026	HOLD	Buy +102.3% avg upside 21 analysts	$71.00 7.70% Upside	+0.0%
MOBI Mobia Medical, Inc.	Jun 02, 2026	BUY	Strong Buy +42.1% avg upside 4 analysts	$15.00 5.28% Upside	·
BSX Boston Scientific	May 27, 2026	BUY	Strong Buy +72.9% avg upside 38 analysts	—	-10.2%
CVRX CVRx	May 12, 2026	SELL	Strong Buy +136.7% avg upside 9 analysts	$6.00 21.30% Upside	-15.9%
PODD Insulet	May 07, 2026	BUY	Strong Buy +79.0% avg upside 32 analysts	$275.00 88.63% Upside	-6.7%
INSP Inspire Medical Systems	May 05, 2026	HOLD	Buy +97.6% avg upside 20 analysts	$54.00 26.81% Upside	-12.4%
DXCM Dexcom	May 04, 2026	HOLD	Strong Buy +38.6% avg upside 32 analysts	$65.00 10.25% Downside	+21.9%
SYK Stryker	May 01, 2026	BUY	Strong Buy +24.0% avg upside 36 analysts	$400.00 29.97% Upside	+2.2%
MMSI Merit Medical Systems	May 01, 2026	BUY	Strong Buy +35.1% avg upside 15 analysts	$77.00 14.58% Upside	+0.9%
GEHC GE Healthcare Technologies Inc	Apr 30, 2026	HOLD	Strong Buy +36.0% avg upside 20 analysts	$65.00 5.56% Upside	+1.2%
CNMD Conmed	Apr 30, 2026	HOLD	Hold +81.2% avg upside 12 analysts	$40.00 22.68% Upside	-0.9%
ZBH Zimmer Biomet Holdings	Apr 29, 2026	HOLD	Buy +27.6% avg upside 37 analysts	$95.00 8.04% Upside	+10.8%
ISRG Intuitive Surgical	Apr 22, 2026	BUY	Strong Buy +29.4% avg upside 36 analysts	$550.00 35.16% Upside	-15.9%
EW Edwards Lifesciences	Mar 30, 2026	BUY	Strong Buy +11.7% avg upside 34 analysts	—	+9.0%
HTFL HeartFlow, Inc.	Mar 25, 2026	BUY	Strong Buy +9.2% avg upside 8 analysts	$35.00 3.96% Upside	+10.5%
IART Integra Lifesciences	Feb 27, 2026	SELL	Buy +136.2% avg upside 21 analysts	$11.00 37.51% Downside	-51.1%
PEN Penumbra	Dec 18, 2025	BUY	Buy +4.4% avg upside 23 analysts	$370.00 16.69% Upside	+0.3%
ABT Abbott Laboratories	Nov 19, 2025	BUY	Strong Buy +31.2% avg upside 35 analysts	$145.00 64.02% Upside	-29.1%
RXST RxSight	Nov 06, 2025	SELL	Hold +132.6% avg upside 13 analysts	$9.00 90.27% Upside	+30.3%
CBLL Ceribell, Inc.	Nov 05, 2025	BUY	Strong Buy +38.7% avg upside 8 analysts	$17.00 5.70% Downside	+46.7%
BLCO Bausch + Lomb Corporation	Oct 30, 2025	HOLD	Buy +30.8% avg upside 19 analysts	$16.00 7.68% Upside	+0.3%
BAX Baxter International	Oct 30, 2025	HOLD	Hold +49.6% avg upside 23 analysts	$19.00 4.42% Downside	+8.8%
ENOV Enovis	Aug 08, 2025	HOLD	Strong Buy +216.5% avg upside 37 analysts	$33.00 50.22% Upside	-12.5%
INGN Inogen	Aug 08, 2025	SELL	Buy +284.8% avg upside 7 analysts	$7.00 9.24% Upside	+1.4%
BDX Becton Dickinson	Aug 07, 2025	HOLD	Buy +35.5% avg upside 25 analysts	$190.00 32.03% Upside	-0.0%
BVS Bioventus	May 06, 2025	HOLD	Strong Buy +41.0% avg upside 8 analysts	$7.00 19.62% Downside	+76.1%
ATRC Atricure	Feb 11, 2025	BUY	Strong Buy +58.1% avg upside 12 analysts	$51.00 77.06% Upside	-20.7%
NPCE NeuroPace	Dec 17, 2024	BUY	Strong Buy +12.2% avg upside 11 analysts	$14.00 10.34% Downside	+35.6%
TMCI Treace Medical Concepts	May 08, 2024	HOLD	Hold +27.0% avg upside 8 analysts	$8.00 90.94% Upside	+80.8%
UTRS Minerva Surgical	Sep 06, 2022	SELL	Buy +799999900.0% avg upside 4 analysts	—	·
AFIB Acutus Medical	Nov 18, 2021	SELL	Sell +61999900.0% avg upside 5 analysts	—	·
SDCCQ SmileDirectClub	Aug 10, 2021	SELL	Sell +513999900.0% avg upside 10 analysts	$6.00 599999900.08% Upside	+74.4%
GKOS Glaukos	May 06, 2021	SELL	Strong Buy +5.5% avg upside 20 analysts	$85.00 34.92% Downside	+50.0%
IRTC Irhythm Technologies	Apr 12, 2021	HOLD	Strong Buy +61.5% avg upside 19 analysts	$95.00 9.13% Downside	+84.1%
TMDX TransMedics Group	May 28, 2019	BUY	Strong Buy +50.5% avg upside 15 analysts	$34.00 56.77% Downside	-54.1%
PENN PENN Entertainment	Jun 08, 2018	BUY	Strong Buy +32.0% avg upside 31 analysts	$40.00 87.80% Upside	-39.1%

🔒 32 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Robbie Marcus — Frequently Asked Questions

How accurate are Robbie Marcus's stock ratings?

Based on the calls 13Foresight could measure, about 56% of Robbie's ratings were profitable over a one-year hold, with an average return of +6.9% per rating, or -1.8% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Robbie ranked on 13Foresight?

Robbie Marcus is currently ranked #1058 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Robbie cover?

Robbie most recently has ratings on MDT, COO, MOBI, BSX, CVRX, PODD, INSP, DXCM, SYK, MMSI, GEHC, CNMD and 25 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!